Clinical Trial Update: Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of IMVAMUNE (MVA-BN) smallpox vaccine in HIV-infected individuals has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• IMVAMUNE (Modified Vaccinia Ankara (MVA))

Snippet

Sponsor: Bavarian Nordic | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2019-01-03